PeptideOS
← Library

Humanin

Mitochondrial-derived peptide

Also known as: HN, HNG (S14G-humanin analog)

Tier 3, Preclinical only

Evidence is limited to animal or in-vitro work. No human pharmacokinetics. Any human dose in circulation is extrapolated, and extrapolation across species routinely fails.

Half-life
Not established

No validated pharmacokinetic half-life located in an allowed primary source. 24-amino-acid peptide encoded in the mitochondrial 16S rRNA region.

Dosing
No established dose

No established human dose. Animal studies use the potent HNG analog on a body-weight basis (e.g., twice-weekly injections in mice); not standardized. Kept qualitative per instructions.

Regulatory status
Not approved. Preclinical/experimental mitochondrial-derived peptide.
Evidence base
animal only · confidence: low

Rodent and cell-model studies (neuroprotection, metabolic healthspan) and mechanistic work; no controlled human efficacy or PK data in allowed sources.

Safety

No human safety data. Preclinical only; safety in humans unestablished. Not for clinical dosing decisions.